Essential Thrombocythemia

• FDA label_change · 2009-07-09
  FDA Approved: AGRYLIN — Supplemental Application (Takeda Pharmaceuticals America, Inc.)

  FDA approved a supplemental NDA for AGRYLIN (anagrelide hydrochloride) submitted by Takeda to modify the product labeling.

• CLINICAL_TRIALS trial_result · 2009-06-02
  Clinical Trial Update: The Pharmacokinetics of Anagrelide in Elderly and Young Patients With Essential Thrombocythaemia (ET) [Phase 2]

  Phase 2 trial update on the pharmacokinetics of anagrelide in elderly and young patients with essential thrombocythemia.

• FDA approval · 2008-06-17
  FDA Approved: AGRYLIN — Supplemental Application (Takeda Pharmaceuticals America, Inc.)

  FDA approved a supplemental application for AGRYLIN (anagrelide hydrochloride) submitted by Takeda Pharmaceuticals America, Inc.

• FDA approval · 2006-09-19
  FDA Approved: DROXIA — Supplemental Application (Waylis Therapeutics LLC)

  FDA approves a supplemental application for DROXIA (hydroxyurea) submitted by Waylis Therapeutics LLC.

• FDA approval · 2006-08-15
  FDA Approved: HYDROXYUREA — Supplemental Application (Endo USA, Inc.)

  The FDA approved a supplemental application for HYDROXYUREA submitted by Endo USA, Inc.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.